Drug intelligence / Profile preview

CM-101

Development stage: Unknown
Lead developer: Chemomab Therapeutics
Administration: Intravenous

Overview

**CM-101** is an investigational Currax obesity program listed by Currax Pharmaceuticals for **obesity maintenance therapy** and shown in the company pipeline at **Phase 2**. Currax does not publicly disclose CM-101's molecular identity, active ingredient composition, pharmacologic target, modality, route of administration, dosage form, or mechanism of action. ([curraxpharma.com](https://www.curraxpharma.com/our-products-pipeline/))

Targets

CCL24 (Chemokine (C-C motif) ligand 24)

Beyond the preview

Go deeper on CM-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CM-101.

Explore the full profile